Przejdź do zawartości
Merck

Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women.

The Journal of clinical endocrinology and metabolism (2014-09-12)
Barbara J Fuhrman, Heather Spencer Feigelson, Roberto Flores, Mitchell H Gail, Xia Xu, Jacques Ravel, James J Goedert
ABSTRAKT

The gut microbiota may influence the risk of breast cancer through effects on endogenous estrogens. The objective of the study was to investigate whether urinary estrogens and estrogen metabolites are associated with the diversity and composition of the fecal microbiome. This was a cross-sectional study among women enrolled in Kaiser Permanente of Colorado. A total of 60 women drawn from a random sample of healthy postmenopausal women (aged 55-69 y), without current or recent use of antibiotics or hormone therapy and no history of cancer or gastrointestinal disease participated in the study. OUTCOME MEASURES AND METHODS: Creatinine-standardized urinary estrogens (estrone and estradiol) and 13 hydroxylated estrogen metabolites were measured in spot urines by liquid chromatography-tandem mass spectrometry. The fecal microbiome was assessed using pyrosequencing of 16S rRNA amplicons. General linear models were used to test for associations of diversity and composition of the fecal microbiome with parent estrogen (estrone + estradiol), total estrogens, and estrogen metabolites and the ratio of estrogen metabolites to parent estrogen, which has been predictive of postmenopausal breast cancer risk in previous studies. The ratio of metabolites to parents was directly associated with whole-tree phylogenetic diversity (R = 0.35, P = .01). Relative abundances of the order Clostridiales (R = 0.32, P = .02) and the genus Bacteroides (R = -0.30, P = .03) were also correlated with the ratio of metabolites to parents. Associations were independent of age, body mass index, and study design factors. Our data suggest that women with a more diverse gut microbiome exhibit an elevated urinary ratio of hydroxylated estrogen metabolites to parent estrogen. Further research is warranted to confirm and relate these findings to clinical disease.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Estriol, ≥97%
Sigma-Aldrich
16-Epiestriol, ≥93% (HPLC)
USP
Estradiol, United States Pharmacopeia (USP) Reference Standard
Supelco
Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material
Estriol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Estriol, meets USP testing specifications
Sigma-Aldrich
Estradiol, meets USP testing specifications
USP
Estron, United States Pharmacopeia (USP) Reference Standard
Supelco
Estrone, Pharmaceutical Secondary Standard; Certified Reference Material
Estrone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Estrone, ≥99%